BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/5/2025 9:35:47 AM | Browse: 154 | Download: 505
 |
Received |
|
2024-12-31 03:45 |
|
Peer-Review Started |
|
2024-12-31 03:45 |
|
First Decision by Editorial Office Director |
|
2025-02-14 09:18 |
|
Return for Revision |
|
2025-02-14 09:18 |
|
Revised |
|
2025-02-23 08:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-03-03 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-03-04 12:32 |
|
Articles in Press |
|
2025-03-04 12:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-05 05:46 |
|
Publish the Manuscript Online |
|
2025-03-05 09:35 |
| ISSN |
1949-8454 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Minireviews |
| Article Title |
Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi and Issa S Al-Amri |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Issa S Al-Amri, Associate Professor, PhD, Department of Biological Sciences and Chemistry, College of Arts and Sciences,, University of Nizwa, P.O. Box 33, Nizwa 616, Ad Dākhilīyah, Oman. issa.alamri@unizwa.edu.om |
| Key Words |
Alcohol-associated liver disease; Elafibranor; PPARα/PPARδ agonist; Macrophages; Liver fibrosis; Inflammatory responses |
| Core Tip |
Macrophages play a central role in the progression of alcohol-associated liver disease (ALD), from initial liver injury to advanced stages like cirrhosis. Elafibranor (EFN), a dual PPARα/δ agonist, offers a promising therapeutic approach by reducing liver fibrosis, inhibiting macrophage activation, and suppressing TLR4/NF-κB inflammatory pathways. Additionally, EFN strengthens intestinal barrier function, addressing key drivers of ALD. With its dual anti-inflammatory and fibrosis-reducing effects, EFN holds potential for ALD and other liver diseases characterized by chronic inflammation and fibrosis. Further research is needed to validate its clinical applications. |
| Publish Date |
2025-03-05 09:35 |
| Citation |
Farhadi S, Mohammadi S, AlKindi AY, Al-Amri IS. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. World J Biol Chem 2025; 16(1): 104535 |
| URL |
https://www.wjgnet.com/1949-8454/full/v16/i1/104535.htm |
| DOI |
https://dx.doi.org/10.4331/wjbc.v16.i1.104535 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
